GoodRx Holdings, Inc.
General ticker "GDRX" information:
- Sector: Health Care
- Industry: Medical - Healthcare Information Services
- Capitalization: $1.6B (TTM average)
GoodRx Holdings, Inc. does not follow the US Stock Market performance with the rate: -20.3%.
Estimated limits based on current volatility of 2.4%: low 2.26$, high 2.37$
Factors to consider:
- Total employees count: 738 (+6.3%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Internal control weaknesses, Labor/talent shortage/retention, Strategic risks and growth management, Customer retention, Market education
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.97$, 4.15$]
- 2026-12-31 to 2027-12-31 estimated range: [2.33$, 4.64$]
Financial Metrics affecting the GDRX estimates:
- Positive: with PPE of 7.8 at the end of fiscal year the price was very low
- Positive: Operating cash flow per share per price, % of 17.22 > 12.96
- Positive: 7.68 < Operating profit margin, % of 13.42
- Negative: negative Industry operating cash flow (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
- Negative: Interest expense per share per price, % of 4.37 > 3.29
- Positive: -8.75 < Industry operating profit margin (median), % of -7.54
- Positive: 42.60 < Shareholder equity ratio, % of 43.89 <= 64.25
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 2.12
- Negative: Investing cash flow per share per price, % of -12.30 <= -4.45
Short-term GDRX quotes
Long-term GDRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $750.26MM | $792.32MM | $796.85MM |
| Operating Expenses | $777.27MM | $726.48MM | $689.88MM |
| Operating Income | $-27.01MM | $65.85MM | $106.97MM |
| Non-Operating Income | $-28.57MM | $-34.39MM | $-50.43MM |
| Interest Expense | $56.73MM | $52.92MM | $42.60MM |
| R&D Expense | $135.84MM | $123.75MM | $121.03MM |
| Income(Loss) | $-55.57MM | $31.46MM | $56.54MM |
| Taxes | $-46.70MM | $15.07MM | $26.10MM |
| Profit(Loss)* | $-8.87MM | $16.39MM | $35.86MM |
| Stockholders Equity | $761.96MM | $724.66MM | $616.26MM |
| Assets | $1,588.80MM | $1,388.07MM | $1,404.06MM |
| Operating Cash Flow | $138.29MM | $183.89MM | $167.90MM |
| Capital expenditure | $55.77MM | $70.35MM | $3.52MM |
| Investing Cash Flow | $-55.77MM | $-70.35MM | $-119.96MM |
| Financing Cash Flow | $-167.40MM | $-337.50MM | $-234.47MM |
| Earnings Per Share** | $-0.02 | $0.04 | $0.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.